TNF-a inhibitors inhibit TNF-a, a central mediator in immunity with important roles in inflammatory cell migration and maturation, granuloma formation and production of inflammatory cytokines. 7, 8 TNF-a inhibition increases susceptibility to invasive fungal infection by defects in cellular immune response due to reduced interferon-γ production, decreased expression of pattern recognition receptors like Toll-like receptors and leucocyte apoptosis. [9] [10] [11] [12] Even though their mechanism of immunosuppression greatly varies, it involves alteration in intracellular signalling, inhibition of cytokine production and reduced leucocyte adhesion and migration. [13] [14] [15] Lastly, glucocorticoids also increase the risk for fungal disease, through reduction in production of pro-inflammatory cytokines, neutrophil adhesion and chemotaxis, macrophage activation and other mechanisms. 16, 17 Fungal infections are a recognised cause of morbidity and poor outcomes in certain populations, such as in patients with haematologic and solid organ malignancy, and critically ill patients. 18, 19 Despite reports of fungal infections in patients with IBD, their clinical and microbiological characteristics have not been extensively described, and their significance in clinical practice and patient outcomes remain unknown. For this reason, the aim of this systematic review was to examine all available evidence in the literature regarding fungal infections in patients with IBD, focusing on the most common fungal causes of infection in IBD and their characteristics,
| ME THODS

| Data search
This review has adopted the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. 20 
| Study selection
Studies that met the following criteria were included in analysis: (i) published in English; (ii) reported clinical data, laboratory data, infection treatment and/or outcomes and (iii) included patients with IBD who were diagnosed with a fungal infection. Studies with any of the following were excluded from analysis: case reports and case series with fewer than 4 patients (most of them were individual case reports); cases of fungal infections of the skin; experimental studies in animals; secondary research papers (eg reviews); editorials, perspectives and papers not reporting results of primary research;
papers irrelevant to fungal infections in patients with IBD; papers not in English. Two investigators (PI, GS) independently reviewed the titles and abstracts of the citations for potentially relevant articles using Abstrackr 21 ; the full-text publications of potentially relevant articles were retrieved and rescreened by the same 2 investigators.
Disagreements were resolved by consensus with a third investigator (CT). Reference lists of included studies were searched for relevant articles.
| Outcomes of interest
The primary study outcome was to record the most common fungal species in patients with IBD. Secondary outcomes were classified into 3 categories: (i) characteristics of fungal infections; (ii) data on IBD and (iii) treatment and outcomes of fungal infections in patients with IBD.
| Data extraction and definitions
Data from each eligible study were independently extracted by 2 investigators (PI, GS 24, 29, 34 The review process is presented graphically in Figure 1 .
| Study characteristics
The 14 included studies involved 1524 patients in total. involving 1454 patients reported risk factors or predisposing conditions for fungal infections in IBD. The predominant condition associated with fungal infection in IBD was use of anti-TNFa agents, which was reported in all studies. 5, 24, 26, 28, 30, 33 In detail, predisposing condi- didaemia. 30 In addition, one study focused on patients with IBD and postoperative Candida infection 34 and 2 studies included IBD patients with spontaneous intra-abdominal Candida abscess. 31, 32 Complications were present in 8 of 22 infections where data were provided. 4, 24, 26, 27, 34 These included (more than one complications occurred in some patients): need for intensive care support (4 infections), 24 sepsis (3 infections), 4,34 disseminated intravascular coagulation (2 infections), 24 surgical wound infection (2 infections) 34 and abscess formation (1 infection). 
| Data on IBD
Sixty-eight patients suffered from Crohn's disease and 5 patients suffered from ulcerative colitis; in 4 studies (1451 patients), 5, 28, 29, 33 the type of IBD was not defined. Duration of disease prior to Two Candida species were isolated in one infection.
TA B L E 2 (Continued) TA B L E 3 Classification of infections per pathogen (n = 1063)
Gastrointestinal tract
Respiratory tract
Bloodstream
Wound infection
Site not reported 
| Treatment and outcomes
Data on treatment of fungal infections were available in 6 studies (24 patients). 24, 26, 29, 29, 32, 34 Antifungal treatment included amphotericin B (8 patients) 24, 26, 34 and triazoles (8 patients), 26, 34 whereas in one study, 29 no treatment was administered in 3 patients. Surgical intervention (either surgery or abscess drainage) was reported in 10 infections. 31, 32, 34 Death related to the infection, according to the study authors, was reported in 104 out of 816 patients with available information on mortality. 4, 5, 24, [26] [27] [28] 34, 35 Of note, nearly all recorded deaths (103 patients) were recorded in one study. number of Candida infections, the sites of Candida infections were not specified. 33 Histoplasma capsulatum was the second most common fungus and was isolated exclusively in studies performed in the USA, where histoplasmosis is endemic. Therefore, local epidemiology remains an important consideration during management of infections in patients with IBD. Management of these infections in IBD patients is not different from other populations, whereas antifungal prophylaxis is currently recommended only for P. jirovecii in patients receiving certain combinations that include immunomodulators.
3,37
A worthwhile remark is that no cases of invasive mould disease were included in this study. One reason is the fact that we excluded studies with few reported cases, consequently excluding numerous case reports. Another reasonable explanation is that the major risk factors for development of invasive aspergillosis are neutropenia and prolonged corticosteroid treatment, which are not the typical features of immunosupression used in patients with IBD. 38 This is also shown in our study, where the majority of invasive fungal infections occurred within a short period of time after initiation of immunosupression. Another explanation could be associated with the pathophysiology of invasive fungal disease by Candida and moulds.
Candida is thought to be able to invade the damaged epithelial barrier of the gut and cause invasive disease, which is quite reasonable in the case of IBD, especially with concurrent immunosuppression. 16 On the other hand, invasive mould disease requires penetration of the alveolar epithelium, with no clear evidence suggesting a defective alveolar epithelium in patients with IBD. 38 Currently available evidence does not allow for safe conclusions on infection severity and mortality. Although we observed considerable mortality rates (>10%), the majority of reported deaths were from one study, 28 whereas exclusion of this study from analysis leaves a much lower reported death rate of 1 out of 56 patients with available outcome data. In addition, the burden of disease caused by fungal infections is difficult to define, as data on the presence or not of complications was available in a total of 22 patients from 5 studies. However, despite current lack of credible data on patient outcomes, it is known that invasive fungal infections carry significant morbidity and mortality and thus, early presumptive antifungal treatment can be of benefit in patients treated for IBD who develop a systematic infection. 8, 16 Fungal infections occurred within 12 months of treatment for IBD, indicating that immune-modifying treatment has an important association with these infections in IBD. In addition, the fact that most of these studies reported treatment with infliximab within 6 months of infection onset, 4, [24] [25] [26] raises the issue of early suspicion of fungal infection in patients with recent initiation of anti-TNFa agents. In line with our findings, a recent meta-analysis of randomised controlled trials showed a much higher relative risk for opportunistic infections in trials with short therapy duration (<8 weeks) compared to trials with longer therapy duration (>8 weeks). 39 Furthermore, a previous review demonstrated that most fungal infections occurred a median of 55 days (IQR, 15-140 days) after initiation of treatment with infliximab. 8 Concern over the risk of infection with the increasing use of biological therapies in IBD has led to several recent meta-analyses on this subject, which demonstrated an increased risk of infections and opportunistic infections in patients treated with biological agents. 6, 40 Corroborating with the above, we further found that prior or current use of anti-TNFa agents was a universal finding in all studies that performed risk factor analysis or explored predisposing factors for fungal infections in patients in IBD. 5, 24, 26, 28, 30, 33 There are certain limitations in our systematic review that should be acknowledged. First, significant heterogeneity between studies, especially as regards to design and outcomes, precludes concrete assumptions in several aspects, such as individual predisposing factors per site of fungal infection, infection severity, treatment and outcomes. Second, despite the notable number of included patients, a large proportion was derived from 2 studies, but only few data from these studies could be used in our review. Future studies should provide a more detailed description of risk factors, clinical characteristics, pathogen distribution and treatment of fungal infections in IBD. In addition, it is necessary to report duration of IBD treatment prior to infection, as well as details of treatment for IBD prior to infection (including type of treatment), to elucidate the association between specific agents and fungal infections.
In conclusion, the present systematic review outlines the clinical and microbiological profile of fungal infections in patients with IBD, with significant clinical implications. Published evidence shows that fungal pathogens, mainly Candida species, should be suspected in infections that occur early during treatment for IBD, especially when TNFa inhibitors are administered.
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